Logo

Ciphergen, University of Kentucky to Collaborate on Ovarian Cancer Dx

Aug 24, 2005

NEW YORK, AUG, 24 (GenomeWeb News) - Ciphergen Biosystems and the University of Kentucky have signed a research and collaboration agreement that will allow the Ciphergen to exclusively license discoveries from partnership's ovarian cancer research for use in diagnostics, Ciphergen said today.

 

According to Paul DePriest, an associate professor of obstetrics and gynecology at UK, the university hopes that the partnership will "accelerate the development of a new diagnostic approach to ovarian cancer" by pairing UK's clinical expertise with Ciphergen's "biomarker discovery and diagnostic process."

 

Ciphergen will be providing UK with its suite of proteomic tools to help researchers analyze patients' tumor cyst fluid and blood for biomarker discovery and development of assays, the company said.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.